Show site search form

Construction of RNA Research and Pilot Manufacturing Facility on track with main works contract awarded

Australia’s first-of-its-kind RNA Research and Pilot Manufacturing Facility is a step closer to reality, with the appointment of the main works contractor Hindmarsh Construction. 

The cutting-edge facility will reduce Australia’s reliance on international supply and provide patients with faster access to new therapies for hard-to-treat diseases such as cancer and rare genetic disorders. 

Located in the Connect Macquarie Park Innovation District at Macquarie University, the new facility will be operated by Myeloid Therapeutics, a global therapeutics company. 

The NSW Government has committed $96 million for the facility, with a further $119 million announced over 10 years for RNA research and development projects. 

The project is being delivered by Health Infrastructure on behalf of the Office of the NSW Chief Scientist & Engineer.  

Construction is expected to commence in the coming months and the facility is expected to be operational in 2026. 

Back to the top of this page